Sotabase

Career

· Earthmetry

Publications (34)

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
The Lancet · 2017
154
cited
Efficacy and safety of topical brepocitinib for the treatment of mild‐to‐moderate atopic dermatitis: a phase IIb, randomized, double‐blind, vehicle‐controlled, dose‐ranging and parallel‐group study
British Journal of Dermatology · 2022
43
cited
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study.
Journal of American Academy of Dermatology · 2022
42
cited
A comparative study of the bias corrected estimates in logistic regression
Statistical Methods in Medical Research · 2008
38
cited
Small-sample comparisons of confidence intervals for the difference of two independent binomial proportions
Computational Statistics & Data Analysis · 2007
33
cited
901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT Study
2015
30
cited
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn’s Disease: Report of the TOSCA Study
Journal of Crohn's & Colitis · 2017
25
cited
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb, randomised, double-blind, vehicle-controlled, parallel-group study.
British Journal of Dermatology · 2023
25
cited
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study
Clinical and Translational Science · 2020
24
cited
Safety, Pharmacokinetic, and Pharmacodynamic Evaluation After Single and Multiple Ascending Doses of a Novel Selective Androgen Receptor Modulator in Healthy Subjects.
Clinical Therapeutics · 2016
23
cited
Bias Reduction in Logistic Regression with Missing Responses When the Missing Data Mechanism is Nonignorable
American Statistician · 2018
22
cited
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study.
The Lancet Rheumatology · 2021
22
cited
Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers
Journal of Crohn's & Colitis · 2019
19
cited
Bias Reduction and a Solution for Separation of Logistic Regression with Missing Covariates
Biometrics · 2009
17
cited
In Search of Ambiguity: A Three-Stage Workflow Design to Clarify Annotation Guidelines for Crowd Workers
Frontiers in Artificial Intelligence · 2021
16
cited
Confidence Interval of the Difference of Two Independent Binomial Proportions Using Weighted Profile Likelihood
Communications in statistics. Simulation and computation · 2008
14
cited
Bias correction in logistic regression with missing categorical covariates
2010
11
cited
OP007 Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of anti-TNF and immunosuppressant experienced Crohn's disease patients who are anti-TNF inadequate responders: Results from the TOSCA study
2014
11
cited
Binomial confidence intervals for testing non-inferiority or superiority: a practitioner’s dilemma
Statistical Methods in Medical Research · 2016
10
cited
Comparison of exact tests for association in unordered contingency tables using standard, mid-p, and randomized test versions
2005
5
cited
Sotabase
Vivek Pradhan | Researcher Profile | Sotabase | Sotabase